SRR12696798
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.700
- INTERFERON_GAMMA_RESPONSE+0.600
- ALLOGRAFT_REJECTION+0.500
- COMPLEMENT+0.500
- APOPTOSIS+0.400
- COAGULATION+0.400
- E2F_TARGETS+0.400
- IL6_JAK_STAT3_SIGNALING+0.400
- INFLAMMATORY_RESPONSE+0.400
- TNFA_SIGNALING_VIA_NFKB+0.400
Top 10 suppressed
- ANGIOGENESIS-0.300
- MYOGENESIS-0.300
- NOTCH_SIGNALING-0.300
- APICAL_JUNCTION-0.200
- HEDGEHOG_SIGNALING-0.200
- KRAS_SIGNALING_DN-0.200
- ADIPOGENESIS-0.100
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.100
- MYC_TARGETS_V2-0.100
- WNT_BETA_CATENIN_SIGNALING-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518244 | — | D | 0.861 |
| 2 | 20020049.LumB | — | D | 0.851 |
| 3 | 20110002.Her2HRneg | — | D | 0.847 |
| 4 | SRR6013516 | — | cohortA1 | 0.844 |
| 5 | BS_XF0ZX2B3 | EPN | Supratentorial EPN | 0.840 |
| 6 | SAMN03290949 | — | — | 0.834 |
| 7 | BS_GJNCYABP | ATRT | — | 0.833 |
| 8 | ERR2208915 | — | — | 0.821 |
| 9 | 8ed1ae0f-90db-445c-9805-f8ae9b55da80 | — | — | 0.812 |
| 10 | TCGA-AO-A03M-01B-11R-A10J-07 | — | C | 0.808 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.700 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.600 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| COMPLEMENT | 0.500 | Inavolisib | — uncovered |
| APOPTOSIS | 0.400 | Idelalisib | — uncovered |
| COAGULATION | 0.400 | Binimetinib | — uncovered |
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.400 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.400 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| PEROXISOME | 0.300 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.300 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.300 | Idelalisib | — uncovered |